Pathogenesis and therapy of psoriasis
- PMID: 17314973
- DOI: 10.1038/nature05663
Pathogenesis and therapy of psoriasis
Abstract
Psoriasis is one of the most common human skin diseases and is considered to have key genetic underpinnings. It is characterized by excessive growth and aberrant differentiation of keratinocytes, but is fully reversible with appropriate therapy. The trigger of the keratinocyte response is thought to be activation of the cellular immune system, with T cells, dendritic cells and various immune-related cytokines and chemokines implicated in pathogenesis. The newest therapies for psoriasis target its immune components and may predict potential treatments for other inflammatory human diseases.
Similar articles
-
Psoriasis: genetic associations and immune system changes.Genes Immun. 2007 Jan;8(1):1-12. doi: 10.1038/sj.gene.6364351. Epub 2006 Nov 9. Genes Immun. 2007. PMID: 17093502 Review.
-
Interplay between keratinocytes and immune cells--recent insights into psoriasis pathogenesis.Int J Biochem Cell Biol. 2009 May;41(5):963-8. doi: 10.1016/j.biocel.2008.10.022. Epub 2008 Nov 5. Int J Biochem Cell Biol. 2009. PMID: 19027868 Review.
-
Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes.Clin Dermatol. 2007 Nov-Dec;25(6):581-8. doi: 10.1016/j.clindermatol.2007.08.013. Clin Dermatol. 2007. PMID: 18021896 Review.
-
[The pathogenesis of inflammatory dermatoses, especially psoriasis].Ned Tijdschr Geneeskd. 2006 Jan 28;150(4):179-83. Ned Tijdschr Geneeskd. 2006. PMID: 16471231 Review. Dutch.
-
Psoriasis: the epidermal component.Clin Dermatol. 2007 Nov-Dec;25(6):589-95. doi: 10.1016/j.clindermatol.2007.09.021. Clin Dermatol. 2007. PMID: 18021897 Review.
Cited by
-
Identifying genetic variants that influence the abundance of cell states in single-cell data.Nat Genet. 2024 Oct;56(10):2068-2077. doi: 10.1038/s41588-024-01909-1. Epub 2024 Sep 26. Nat Genet. 2024. PMID: 39327486
-
Pustular Psoriasis Induced by Dupilumab: A Case Report.J Inflamm Res. 2024 Sep 16;17:6389-6394. doi: 10.2147/JIR.S476297. eCollection 2024. J Inflamm Res. 2024. PMID: 39310904 Free PMC article.
-
Clinical and molecular insights into cardiovascular disease in psoriatic patients and the potential protective role of apremilast.Front Immunol. 2024 Aug 7;15:1459185. doi: 10.3389/fimmu.2024.1459185. eCollection 2024. Front Immunol. 2024. PMID: 39170613 Free PMC article. Review.
-
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.Dermatol Ther (Heidelb). 2024 Aug;14(8):2235-2248. doi: 10.1007/s13555-024-01224-x. Epub 2024 Jul 30. Dermatol Ther (Heidelb). 2024. PMID: 39080153 Free PMC article.
-
Ca2+ transients on the T cell surface trigger rapid integrin activation in a timescale of seconds.Nat Commun. 2024 Jul 20;15(1):6131. doi: 10.1038/s41467-024-50464-0. Nat Commun. 2024. PMID: 39033133 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical